Disease

NFL players spotlight Sickle Cell Disease Association of America

Retrieved on: 
Friday, December 2, 2022

HANOVER, Md., Dec. 2, 2022 /PRNewswire-PRWeb/ -- San Francisco 49ers running back Tevin Coleman and Arizona Cardinals linebacker Markus Golden will support the Sickle Cell Disease Association of America through the NFL's My Cause My Cleats program by wearing custom-designed cleats with inspirational artwork and messages to raise awareness and engagement around sickle cell disease.

Key Points: 
  • "We're thrilled and grateful to Tevin and Markus for recognizing the Sickle Cell Disease Association of America on their cleats this year," said Regina Hartfield, president and CEO of the Sickle Cell Disease Association of America.
  • Pfizer partners with the Sickle Cell Disease Association of America to advance education and awareness of sickle cell disease.
  • He has featured the Sickle Cell Disease Association of America and sickle cell causes on his cleats in past years.
  • "I lost my cousin Jonah at only 10 years old to the disease, and that's why I'm so driven to bring attention to sickle cell and the Sickle Cell Disease Association of America on my cleats this year.

Announcing Andrew A. Wilson MD as the Alpha-1 Foundation's new Scientific Director

Retrieved on: 
Friday, December 2, 2022

CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.

Key Points: 
  • CORAL GABLES, Fla., Dec. 2, 2022 /PRNewswire/ -- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director.
  • Dr. Wilson assumes this role with a long-standing passion and commitment to the Alpha-1 community.
  • "I am honored and humbled to have been selected as the new Scientific Director of the Alpha-1 Foundation.
  • I hope that as Scientific Director I will be able to help the Foundation to advance its mission and work towards a cure for AATD."

DBGI Expects Closing of Sundry Acquisition In Next Two Weeks

Retrieved on: 
Friday, December 2, 2022

"The Sundry acquisition is expected to contribute significant revenue scale and operating leverage," said Hil Davis, Chief Executive Officer of DBG.

Key Points: 
  • "The Sundry acquisition is expected to contribute significant revenue scale and operating leverage," said Hil Davis, Chief Executive Officer of DBG.
  • "We believe adding Sundry to our Bailey Shop, which is our multi-brand e-commerce site( www.bailey44.com )will contribute revenueimmediately.
  • We offer a wide variety of apparel through numerous brands on a both direct-to-consumer and wholesale basis.
  • Certain statements included in this release are "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the acquisition and the ability to meet the closing conditions required to complete the acquisition.

Tuberculosis Diagnostics Global Market Report 2022: High Prevalence in the Developing World Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Tuberculosis Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tuberculosis Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report on global tuberculosis diagnostics market studies various tuberculosis diagnostics test type.
  • Healthcare regulatory agencies such as WHO, CDC are taking initiatives towards global awareness of tuberculosis and improvising the diagnostic methods.
  • The global tuberculosis diagnostics market is growing at a CAGR of 4.5% during the forecast period from 2022 to 2030.

Global Project Portfolio Management Market Analysis Report 2022: A $6.5 Billion Market by 2027 - Asia-Pacific to Emerge as Best Market for Investments - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The project portfolio management market size is expected to grow from USD 4.7 Billion in 2022 to USD 6.5 Billion by 2027, at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period.

Key Points: 
  • The project portfolio management market size is expected to grow from USD 4.7 Billion in 2022 to USD 6.5 Billion by 2027, at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period.
  • Project Portfolio Management market is rapidly gaining acceptance worldwide by enterprises and corporates.
  • PPM solutions and associated services are implemented by organizations and their stakeholders to manage multiple projects and maximize the impact of each project by making the best utilization of business resources.
  • On the basis of service, the PPM market is categorized into two segments: consulting and implementation services, and training, support, and maintenance services.

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Friday, December 2, 2022

I look forward to additional data on UGN-102, including evidence from the ENVISION Phase 3 study.

Key Points: 
  • I look forward to additional data on UGN-102, including evidence from the ENVISION Phase 3 study.
  • Patients who completed the OPTIMA II study were eligible to participate in this rollover study.
  • At the time of data cut off (February 25, 2022), data were available for 15 of the 25 patients.
  • Patients achieving CR were followed quarterly to 12 months after initiation of study treatment to evaluate safety, efficacy, and durability.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
Friday, December 2, 2022

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Retrieved on: 
Friday, December 2, 2022

BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial.

Key Points: 
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to advance our portfolio of neurology-focused programs.
  • We also look forward to meeting with leading epileptologists, including Xenon trial investigators, as well as patient advocacy groups at this important meeting.
  • We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

Retrieved on: 
Friday, December 2, 2022

To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.

Key Points: 
  • To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.
  • In partnership with CMS, we believe that, if approved, ruxolitinib cream will be an innovative therapeutic option poised to also help patients and healthcare providers in Greater China.
  • We are very honored to partner with Incyte on ruxolitinib cream in Greater China and Southeast Asia.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.